Travere Therapeutics, Inc.
NASDAQ:TVTXBiotechnology
+$0.65 today
- Market cap
- $4.82B
- Beta
- 1.14
- P/E (TTM)
- -235.0
- EPS (TTM)
- -$0.23
Volume 0.84M
Average 2.31M
TVTX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Travere Therapeutics, Inc.NASDAQ: TVTX
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization declines year over year
Q3 FY2026 depreciation & amortization of $5.2M fell 67.1% year over year, behind the -3.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at +43.1% a year.
Context
- Depreciation & amortization amounted to 12.4% of revenue in FY2025, down 6.3 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -67.1% toward the trailing-twelve-month pace of -3.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 60.74M USD
- Year-over-year change
- +39.5%
- 4-year CAGR
- +47.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.74M | +39.5% |
| FY2024 | 2024-12-31 | 43.56M | +13.0% |
| FY2023 | 2023-12-31 | 38.53M | +86.0% |
| FY2022 | 2022-12-31 | 20.72M | +62.6% |
| FY2021 | 2021-12-31 | 12.75M | — |
Depreciation & Amortization vs competitors
How TVTX compares with its peers on the latest reported figures
- TVTX's LTM Sep 2026 depreciation & amortization of $52.78M is the largest of the 5 companies compared; the peer median is $4.26M.
- Its year-over-year change of -3.5% is the 3rd highest of 5, against a peer median of -10.7%.
- Depreciation & amortization amounts to 8.1% of revenue for TVTX, versus a peer median of 10.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $52.78M | -3.5% | +43.1% | 8.1% | |
| LTM Mar 2026 | $8.54M | -34.4% | — | 2.3% | |
| LTM Mar 2026 | $6.36M | +7.2% | +29.4% | 715.2% | |
| LTM Mar 2026 | $2.16M | -28.6% | -14.3% | 10.8% | |
| LTM Jun 2026 | $154K | +170.2% | — | — | |
| Peer median (excluding TVTX) | $4.26M | -10.7% | +7.5% | 10.8% | |
Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (217.29M) | (331.47M) | (376.33M) | (320.63M) | (25.55M) |
| Depreciation & Amortization | 12.75M | 20.72M | 38.53M | 43.56M | 60.74M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 29.57M | 38.14M | 44.25M | 36.91M | 44.87M |
| Change in Working Capital | 80.78M | 875K | (25.48M) | (63.02M) | (14M) |
| Accounts Receivables | 17.95M | (1.43M) | (11.3M) | (6.04M) | (27.82M) |
| Inventory | 117K | (1.21M) | (39.42M) | (3.77M) | 5.02M |
| Accounts Payables | 2.47M | 2.06M | 24.76M | (17.56M) | (85K) |
| Other Working Capital | 60.24M | 1.46M | 481K | (35.64M) | 8.89M |
| Other Non-Cash Items | 79.41M | 85.44M | 39.01M | 65.71M | (28.28M) |
| Operating Cash Flow | (14.79M) | (186.29M) | (280.02M) | (237.48M) | 37.78M |
| Capital Expenditures | (24.15M) | (28.37M) | (41.59M) | (101.21M) | (58.16M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (547.08M) | (385.39M) | (443.94M) | (125.76M) | (237.14M) |
| Sales of Investments | 433.6M | 381.99M | 334.58M | 326.33M | 323.6M |
| Other Investing Activities | (19.05M) | (28.97M) | 165.81M | (40K) | (404K) |
| Investing Cash Flow | (137.62M) | (32.55M) | 55.78M | 99.33M | 27.89M |
| Debt Repayment | 0 | 104.93M | 0 | 0 | (68.9M) |
| Common Stock Issued | 224.93M | 19.55M | 191.2M | 134.74M | 37.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.75M | (6.9M) | 27.55M | 4.68M | (2.1M) |
| Financing Cash Flow | 231.68M | 117.57M | 218.75M | 139.42M | (33.47M) |
| Effect of Forex Changes | 1.71M | (2.79M) | 1.98M | (913K) | 2.29M |
| Net Change in Cash | 80.98M | (104.07M) | (3.51M) | 359K | 34.5M |
| Free Cash Flow | (38.94M) | (214.66M) | (321.61M) | (338.69M) | (20.37M) |
Travere Therapeutics, Inc.
NASDAQ:TVTX
Intrinsic Alpha fair value
Locked
Current Price
$50.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.